PMID- 10362086
OWN - NLM
STAT- MEDLINE
DCOM- 19990629
LR  - 20191210
IS  - 0022-4790 (Print)
IS  - 0022-4790 (Linking)
VI  - 71
IP  - 1
DP  - 1999 May
TI  - Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived 
      peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an 
      HLA-A2 esophageal cancer patient.
PG  - 16-21
AB  - BACKGROUND AND OBJECTIVES: Using peripheral blood mononuclear cells (PBMCs) from 
      a 10-year survivor with established human leukocyte antigen (HLA)-A2(+) and 
      MAGE-3(+) esophageal cancer cell line (KYSE-170), we examined the induction of 
      HLA-A2-restricted and MAGE-3-gene-derived peptide (FLWGPRALV, amino acids 
      271-279)-specific cytolytic T lymphocytes (CTLs). METHODS: Autologous dendritic 
      cells (DCs) cultured with granulocyte-macrophage colony stimulating factor and 
      interleukin-4 were used as antigen presenting cells. PBMCs were stimulated by 
      peptide-pulsed DCs in vitro. RESULTS: PBMC cocultured with FLWGPRALV-pulsed DCs 
      could induce the relevant peptide-specific CTLs, which had tumor necrosis factor 
      production and specific cytotoxicity against relevant peptide-pulsed autologous 
      DCs (34%, effector:target ratio = 40:1). Moreover, they showed specific 
      cytotoxicity against the autologous esophageal cancer cell line KYSE-170 (17%, 
      effector:target ratio = 40:1). CONCLUSIONS: These results suggest that 
      FLWGPRALV-pulsed cultured DCs would be a potent candidate for peptide vaccine 
      against HLA-A2(+) and MAGE-3(+) esophageal cancer.
FAU - Kanaoka, S
AU  - Kanaoka S
AD  - Department of Surgery and Surgical Basic Science, Graduate School of Medicine, 
      Kyoto University, Japan. kanaoka@kuhp.kyoto-u.ac.jp
FAU - Yamasaki, S
AU  - Yamasaki S
FAU - Okino, T
AU  - Okino T
FAU - Inoue, N
AU  - Inoue N
FAU - Shimada, Y
AU  - Shimada Y
FAU - Kaneko, M
AU  - Kaneko M
FAU - Otaka, A
AU  - Otaka A
FAU - Fujii, N
AU  - Fujii N
FAU - Imamura, M
AU  - Imamura M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 119425-35-3 (A2-binding peptide)
SB  - IM
MH  - Antigen-Presenting Cells/immunology
MH  - *Antigens, Neoplasm
MH  - Dendritic Cells/immunology
MH  - Esophageal Neoplasms/immunology/pathology/*therapy
MH  - HLA-A2 Antigen
MH  - Humans
MH  - *Immunotherapy, Active
MH  - Intercellular Signaling Peptides and Proteins
MH  - *Neoplasm Proteins
MH  - *Peptides
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
EDAT- 1999/06/11 10:00
MHDA- 2000/06/20 09:00
CRDT- 1999/06/11 10:00
PHST- 1999/06/11 10:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/06/11 10:00 [entrez]
AID - 10.1002/(SICI)1096-9098(199905)71:1<16::AID-JSO4>3.0.CO;2-A [pii]
AID - 10.1002/(sici)1096-9098(199905)71:1<16::aid-jso4>3.0.co;2-a [doi]
PST - ppublish
SO  - J Surg Oncol. 1999 May;71(1):16-21. doi: 
      10.1002/(sici)1096-9098(199905)71:1<16::aid-jso4>3.0.co;2-a.